ArticleAmerican journal of translational research2026
Efficacy and safety of levetiracetam intravenous infusion combined with midazolam continuous pump infusion for stepwise emergency treatment of convulsive status epilepticus in children: a retrospective cohort study.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the efficacy and safety of intravenous levetiracetam (LEV) combined with continuous midazolam (MDZ) infusion versus MDZ monotherapy as second-line treatment for pediatric convulsive status epilepticus (CSE).
methodsThis retrospective cohort study included 159 pediatric patients with generalized convulsive status epilepticus (GCSE) treated between June 2017 and December 2025. Patients received either LEV+MDZ (n=86) or MDZ alone (n=73). Outcomes included seizure cessation at 20 and 40 minutes, 24-hour seizure control, requirement for third-line antiseizure medication, adverse events, change in Status Epilepticus Severity Score (STESS), lengths of pediatric intensive care unit (PICU), and Pediatric Cerebral Performance Category (PCPC) score at discharge.
resultsCompared to MDZ monotherapy, the combination group showed significantly greater reduction in STESS at 24 hours (1.94 ± 0.46 vs. 2.67 ± 0.53,
conclusionsEarly administration of LEV combined with MDZ was associated with reduced seizure severity, decreased need for rescue therapy, lower benzodiazepine exposure, shorter hospitalization, and improved short-term neurological outcome without increasing adverse events in pediatric patients with CSE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.